10-Q: Alkermes Reports Q2 2026 Results, Driven by LUMRYZ Acquisition

Alkermes plc announced its second-quarter 2026 financial results, highlighting revenue growth from LUMRYZ and increased operating expenses due to the Avadel acquisition.

Summary

• Alkermes plc reported a net income of $0.5 million for the three months ended June 30, 2026, a decrease from $87.1 million in the same period last year, primarily due to increased operating and interest expenses related to the Avadel acquisition.
• For the six months ended June 30, 2026, the company reported a net loss of $66.0 million, compared to a net income of $109.6 million in the prior year, also driven by higher expenses from the Avadel acquisition.
• Total revenues increased to $496.0 million for the quarter and $888.9 million for the six months, up from $390.7 million and $697.2 million respectively, largely due to the inclusion of LUMRYZ sales.
• The Avadel Acquisition, completed on February 12, 2026, significantly impacted the balance sheet with increased goodwill and intangible assets, and the financial statements reflect the operations of Avadel from the closing date.
• The company has $511.5 million in cash and cash equivalents and $731.2 million in restricted cash as of June 30, 2026, and expects existing cash to be sufficient for at least the next twelve months.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant decrease in profitability and the substantial increase in expenses and debt resulting from the Avadel acquisition, despite revenue growth.

Positives

• Total revenues increased by 27% for the quarter and 28% for the six-month period, driven by the addition of LUMRYZ and increased sales of LYBALVI.
• LUMRYZ, acquired through the Avadel acquisition, contributed $96.6 million in product sales in its first partial quarter of inclusion.
• LYBALVI sales increased by 11.4% for the quarter and 19.4% for the six-month period.
• ARISTADA and ARISTADA INITIO sales saw a 7% increase in units sold for the six-month period.
• The company has a strong cash position with $511.5 million in cash and cash equivalents and $731.2 million in restricted cash as of June 30, 2026.
• The company expects its current cash, cash equivalents, and investments to be sufficient to finance its anticipated working capital and other cash requirements for at least the next twelve months.

Negatives

• Net income decreased significantly to $0.5 million for the quarter and a net loss of $66.0 million was reported for the six-month period, compared to substantial net income in the prior year.
• Total operating expenses increased by $180.0 million for the quarter and $328.5 million for the six-month period, largely due to the Avadel acquisition.
• Interest expense increased significantly due to new debt financing for the Avadel acquisition.
• The company incurred $1.1 million and $35.9 million in transaction costs related to the Avadel Acquisition during the three and six months ended June 30, 2026, respectively.
• Manufacturing and royalty revenues decreased by $6.3 million for the six-month period, primarily due to the conclusion of VUMERITY manufacturing subcontracting obligations.

Risks

• The company faces patent infringement lawsuits related to LYBALVI from Teva, Apotex, and MSN, alleging invalidity, unenforceability, or non-infringement of Alkermes' patents.
• An antitrust class action lawsuit has been filed by Value Drug Company alleging fraudulent patent procurement and enforcement for VIVITROL, seeking unspecified damages.
• The company is subject to a civil investigative demand from a U.S. state governmental authority.
• The company's future results could be adversely affected if its development projects are not successfully completed or if acquired intangible assets become impaired.
• The company is exposed to non-U.S. currency exchange risk, primarily related to royalty revenues.

Future Outlook

The company expects its existing cash, cash equivalents, and investments to be sufficient to finance its anticipated working capital and other cash requirements, including debt service and capital expenditures, for at least the twelve months following the date of issuance. Subject to market conditions, interest rates, and other factors, the company may pursue additional financing opportunities in the future.

Management Comments

• The decrease in net income for the three months ended June 30, 2026, as compared to the three months ended June 30, 2025, was primarily due to increases in total operating expenses and interest expense, which were primarily related to the Avadel Acquisition.
• The increase in total revenues during the three months ended June 30, 2026, as compared to the three months ended June 30, 2025, was primarily due to the addition of LUMRYZ to our proprietary product portfolio.
• The company expects that its existing cash, cash equivalents and investments will be sufficient to finance its anticipated working capital and other cash requirements, including debt service and capital expenditures, for at least the twelve months following the date from which our financial statements were issued.

Industry Context

StockSavvy.ai notes that Alkermes' results reflect the ongoing consolidation trend in the biopharmaceutical sector, with significant acquisitions like the Avadel deal impacting financial performance and strategic positioning. The company's focus on neuroscience aligns with a growing area of unmet medical need.

Comparison to Industry Standards

• The reported revenue growth for LUMRYZ and LYBALVI is competitive within the specialty pharmaceutical market, where new product launches often drive significant top-line increases.
• The substantial increase in R&D expenses is consistent with industry practices for companies investing in late-stage clinical trials and pipeline development, particularly in complex therapeutic areas like neuroscience.
• The integration of a significant acquisition like Avadel Pharmaceuticals is a common strategy for mid-to-large biopharma companies seeking to expand their product portfolios and market reach, though it often leads to short-term increases in debt and operating expenses.

Legal Proceedings

• Alkermes Pharma Ireland Limited (APIL) and Alkermes, Inc. have filed patent infringement lawsuits against Teva, Apotex, and MSN regarding generic versions of LYBALVI.
• Value Drug Company filed an antitrust class action lawsuit against Alkermes, Inc. and APIL concerning VIVITROL patent enforcement.
• The company is cooperating with a civil investigative demand from a U.S. state governmental authority.
• The Second Circuit Court affirmed a prior decision in favor of Alkermes regarding litigation with Acorda Therapeutics, Inc.

Stakeholder Impact

• Shareholders may be concerned about the significant decrease in net income and the increased debt load following the Avadel acquisition.
• Employees may be impacted by integration activities and potential restructuring following the Avadel acquisition.
• Customers and healthcare providers will continue to have access to Alkermes' portfolio of neuroscience medicines, including the newly acquired LUMRYZ.

Next Steps

• Continue to defend intellectual property related to LYBALVI against patent infringement lawsuits.
• Continue to vigorously defend against the antitrust class action litigation for VIVITROL.
• Cooperate with the U.S. state governmental authority regarding the civil investigative demand.
• Complete the purchase price allocation for the Avadel Acquisition within one year of the Closing Date.
• Monitor and manage the integration of Avadel Pharmaceuticals into Alkermes' operations.

Key Dates

Recommendation

While revenue growth is positive, the significant increase in expenses and debt due to the Avadel acquisition, coupled with ongoing legal challenges, warrants a cautious 'hold' rating. Investors should monitor the integration of Avadel and the resolution of legal proceedings.

Keywords

Alkermes, LUMRYZ, Avadel Acquisition, Narcolepsy, Schizophrenia, Bipolar Disorder, Neuroscience, Biopharmaceutical